A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies
作者
J. Nehra,Penelope A. Bradbury,Peter Ellis,Janessa Laskin,Christian Kollmannsberger,Desirée Hao,Rosalyn A. Juergens,G. Goss,Paul Wheatley‐Price,Sebastién J. Hotte,Karen A. Gelmon,A. Tinker,Pamela Brown-Walker,L. Gauthier,Dongsheng Tu,Xuyang Song,Adeel Khan,Lesley Seymour,Martin Smoragiewicz